摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-isopropyl-pyridin-3-yl)-ethanone | 435273-46-4

中文名称
——
中文别名
——
英文名称
1-(4-isopropyl-pyridin-3-yl)-ethanone
英文别名
1-(4-Isopropylpyridin-3-yl)ethanone;1-(4-propan-2-ylpyridin-3-yl)ethanone
1-(4-isopropyl-pyridin-3-yl)-ethanone化学式
CAS
435273-46-4
化学式
C10H13NO
mdl
MFCD08447081
分子量
163.219
InChiKey
FGNXOQIMDXTCQJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    274.5±28.0 °C(Predicted)
  • 密度:
    0.993±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    30
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    1-(4-isopropyl-pyridin-3-yl)-ethanone 、 4-Methyl-3-(2-chloroacetyl)pyridine 生成 4-(2-Propyl)-3-(2-chloroacetyl)pyridine
    参考文献:
    名称:
    3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors
    摘要:
    本发明提供了一种带有3-吡啶基或4-异喹啉基取代基的新型噻唑,并提供了其制药组合物。本发明还提供了使用本发明化合物和制药组合物作为裂解酶抑制剂(例如17a-羟基酶-C17,20酶)的方法。本发明还提供了治疗患者癌症的方法,包括向患者投药本发明化合物或制药组合物。癌症可以是前列腺癌或乳腺癌等。
    公开号:
    US20040267017A1
点击查看最新优质反应信息

文献信息

  • PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION
    申请人:ZHANG Yan
    公开号:US20120129843A1
    公开(公告)日:2012-05-24
    This invention relates to thiazole I and its therapeutic and prophylactic uses, wherein the variables R z , Q, J, R 1 , R 3 , R 5 , and R 6 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.
    这项发明涉及噻唑I及其治疗和预防用途,其中变量Rz、Q、J、R1、R3、R5和R6在规范中有定义。治疗和/或预防的疾病包括类风湿关节炎。
  • PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL
    申请人:KANTO KAGAKU KABUSHIKI KAISHA
    公开号:US20150031920A1
    公开(公告)日:2015-01-29
    [Object] The object of this invention is to provide a method for producing an optically active secondary alcohol at a high optical purity by hydrogenating a substrate carbonyl compound at a high efficiency using as a catalyst a ruthenium complex bearing as a ligand certain optically active diphosphine compound and a readily synthesized amine compound. [Solution] The method of producing an optically active secondary alcohol according to the present invention is characterized in that a substrate carbonyl compound (provided that 3-quinuclidinone, 3-quinuclidinone derivative having a substituent, and a ketone having an aromatic hydrocarbon group and a heterocycle are excluded) is reacted with hydrogen and/or a hydrogen donating compound in the presence of a ruthenium complex selected from the compounds expressed by following general formula (1) RuXYAB (1) [in the general formula (1), X and Y are the same or different from each other and denote a hydrogen atom or an anionic group, A denotes an optically active diphosphine expressed by the general formula (2), B denotes an amine compound expressed by following general formula (3)].
    本发明的目的是提供一种通过在高效率下使用一种作为催化剂的钌配合物,其中该钌配合物携带某种光学活性的二膦化合物和一种易于合成的胺化合物,从而在高光学纯度下加氢化底物羰基化合物生产光学活性二级醇的方法。 根据本发明的一种生产光学活性二级醇的方法的特征在于,在一种选择自下述通用式(1)RuXYAB所表示的化合物的钌配合物的存在下,将底物羰基化合物(假设排除3-喹啉酮、带有取代基的3-喹啉酮衍生物以及具有芳香烃基和杂环的酮)与氢气和/或氢供体化合物反应。[在通用式(1)中,X和Y相同或不同,表示氢原子或阴离子基团,A表示由通用式(2)表示的光学活性二膦,B表示由下述通用式(3)表示的胺化合物]。
  • Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
    申请人:——
    公开号:US20040072876A1
    公开(公告)日:2004-04-15
    The present invention provides a pharmaceutical composition having a steroid C 17,20 -lyase inhibitory activity, which is useful as a prophylactic or therapeutic agent of prostatism, tumor such as breast cancer and the like, more particularly, a steroid C 17,20 -lyase inhibitor containing a compound represented by the formula: 1 wherein A 1 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, one of A 2 and A 3 is a hydrogen atom, a halogen atom, a C 1-4 aliphatic hydrocarbon group optionally having substituents or an optionally esterified carboxyl group, the other of A 2 and A 3 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, and at least one of A 1 , A 2 and A 3 is a 3-pyridyl group optionally having substituents, or a salt thereof or a prodrug thereof.
    本发明提供了一种具有类固醇C17,20-裂解酶抑制活性的药物组合物,其可作为前列腺增生症、乳腺癌等肿瘤的预防或治疗剂,更具体地,是一种含有以下化合物的类固醇C17,20-裂解酶抑制剂:式中,A1为芳香族碳氢基团,可选地具有取代基,或者为杂环基团,可选地具有取代基;A2和A3中的一个为氢原子、卤素原子、C1-4脂肪族碳氢基团,可选地具有取代基,或者为可选酯化的羧基;另一个为芳香族碳氢基团,可选地具有取代基,或者为杂环基团,可选地具有取代基;且A1、A2和A3中至少有一个为可选地具有取代基的3-吡啶基团,或其盐或前药。
  • METHODS AND COMPOSITIONS RELATED TO WRAPPING OF DEHYDRONS
    申请人:Fernandez Ariel
    公开号:US20130131076A1
    公开(公告)日:2013-05-23
    This application describes a novel technology in drug discovery and drug-based imaging/detection: the wrapping technology. This technology is based on identified singularities in the structure of soluble proteins. In contrast with drug-design approaches based on standard structural considerations, the packing of a protein, or more precisely, its dehydron pattern, may be used as a selectivity filter to design small-molecule inhibitors. The wrapping technology described herein is a novel form of rational drug design for avoiding side effects in drug therapy and sharpening the inhibitory impact of drugs on the oncokinome.
    该应用程序描述了一种新型的药物发现和药物成像/检测技术:包覆技术。该技术基于可溶性蛋白质结构中的特异性。与基于标准结构考虑的药物设计方法相比,蛋白质的包装,或更准确地说,其脱水模式,可以用作选择性过滤器来设计小分子抑制剂。在此描述的包覆技术是一种新型的理性药物设计形式,可避免药物治疗的副作用,并增强药物对肿瘤蛋白组的抑制作用。
  • Process for producing optically active secondary alcohol
    申请人:Kanto Kagaku Kabushiki Kaisha
    公开号:EP2865446A1
    公开(公告)日:2015-04-29
    The object of this invention is to provide a method for producing an optically active secondary alcohol at a high optical purity by hydrogenating a substrate carbonyl compound at a high efficiency using as a catalyst a ruthenium complex bearing as a ligand certain optically active diphosphine compound and a readily synthesized amine compound. The method of producing an optically active secondary alcohol according to the present invention is characterized in that a substrate carbonyl compound (provided that 3-quinuclidinone, 3-quinuclidinone derivative having a substituent, and a ketone having an aromatic hydrocarbon group and a heterocycle are excluded) is reacted with hydrogen and/or a hydrogen donating compound in the presence of a ruthenium complex selected from the compounds expressed by following general formula (1) RuXYAB (1) [in the general formula (1), X and Y are the same or different from each other and denote a hydrogen atom or an anionic group, A denotes an optically active diphosphine expressed by the general formula (2), B denotes an amine compound expressed by following general formula (3)].
    本发明的目的是提供一种高光学纯度的光学活性仲醇的制取方法,该方法是以某种光学活性二膦化合物和易于合成的胺化合物为配体的钌络合物为催化剂,通过高效率地氢化底物羰基化合物来制取光学活性仲醇。 根据本发明的生产光学活性仲醇的方法,其特征在于底物羰基化合物(但不包括3-奎宁环酮、具有取代基的3-奎宁环酮衍生物和具有芳香烃基和杂环的酮)在选自通式(1)RuXYAB(1)的化合物的钌络合物存在下与氢和/或氢捐赠化合物反应[在通式(1)中、X 和 Y 彼此相同或不同,表示氢原子或阴离子基团,A 表示通式 (2) 所表示的光学活性二膦,B 表示通式 (3) 所表示的胺化合物]。
查看更多